Evidence map›Paper›PMID 37732244›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Deep Learning Model for Tumor Type Prediction using Targeted Clinical Genomic Sequencing Data.

Madison Darmofal, Shalabh Suman, Gurnit Atwal, Jie-Fu Chen, Jason C Chang, Michael Toomey, Efsevia Vakiani, Anna M Varghese, Anoop Balakrishnan Rema, Aijazuddin Syed and 3 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Madison DarmofalComputational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Shalabh SumanDepartment of Pathology, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Gurnit AtwalComputational Biology Program, Ontario Institute for Cancer Research; Toronto, ON M5G 0A3, Canada.
Jie-Fu ChenDepartment of Pathology, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Jason C ChangDepartment of Pathology, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Michael ToomeyComputational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Efsevia VakianiDepartment of Pathology, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Anna M VargheseDepartment of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Anoop Balakrishnan RemaDepartment of Pathology, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Aijazuddin SyedDepartment of Pathology, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Nikolaus SchultzMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Michael BergerDepartment of Pathology, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Quaid MorrisComputational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Memorial Sloan Kettering Cancer Center · USOntario Institute for Cancer Research · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
MSK Computational Biology Summer ProgramR25CA233208 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Michael F. Berger, Yaihara Myriam Fortis-Santiago · 2019 to 2026
$1.8M
NCI NIH HHS P30 CA008748NCI NIH HHS R25 CA233208
6 · The paper itself

Abstract

Tumor type guides clinical treatment decisions in cancer, but histology-based diagnosis remains challenging. Genomic alterations are highly diagnostic of tumor type, and tumor type classifiers trained on genomic features have been explored, but the most accurate methods are not clinically feasible, relying on features derived from whole genome sequencing (WGS), or predicting across limited cancer types. We use genomic features from a dataset of 39,787 solid tumors sequenced using a clinical targeted cancer gene panel to develop Genome-Derived-Diagnosis Ensemble (GDD-ENS): a hyperparameter ensemble for classifying tumor type using deep neural networks. GDD-ENS achieves 93% accuracy for high-confidence predictions across 38 cancer types, rivalling performance of WGS-based methods. GDD-ENS can also guide diagnoses on rare type and cancers of unknown primary, and incorporate patient-specific clinical information for improved predictions. Overall, integrating GDD-ENS into prospective clinical sequencing workflows has enabled clinically-relevant tumor type predictions to guide treatment decisions in real time.

Identifiers

PMID37732244
PMCPMC10508812
OpenAlexW4386583481

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.